Pfizer’s RSV vaccine was over 90% effective at preventing severe outcomes from respiratory syncytial virus (RSV) in older adults, according to a new study. Previous studies have shown the vaccine to be highly effective at preventing hospitalization and ER visits from RSV. This new study built on this research, finding that the vaccine protected more than 90% of patients against specific bad outcomes like ICU admission and mechanical ventilation.
The CDC recommends the RSV vaccine for all adults age 75+ as well as adults age 50-74 at heightened risk for severe illness. The CDC also recommends the Pfizer vaccine for pregnant individuals.
RSV activity is picking up in the US, particularly in the Southern states. Each year, the virus hospitalizes up to 160,000 seniors, 10,000 of whom die from their infection.
Full Story: Healio
